NASDAQ:SOLY - Soliton Stock Price, Forecast & News

Soliton trades on the NASDAQ under the ticker symbol "SOLY."

1 Wall Street analysts have issued 12 month price targets for Soliton's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Soliton's share price to reach $22.00 in the next year. This suggests a possible upside of 85.5% from the stock's current price. View Analyst Price Targets for Soliton.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soliton in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soliton.

News headlines about SOLY stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soliton earned a news impact score of 1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Soliton.

Soliton saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,130,000 shares, a decline of 5.0% from the December 31st total of 1,190,000 shares. Based on an average daily trading volume, of 214,800 shares, the short-interest ratio is presently 5.3 days. Approximately 17.8% of the shares of the stock are short sold. View Soliton's Current Options Chain.

Some companies that are related to Soliton include Orthopediatrics (KIDS), Cerus (CERS), Orthofix Medical (OFIX), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), MiMedx Group (MDXG), Inovio Pharmaceuticals (INO), OraSure Technologies (OSUR), Utah Medical Products (UTMD) and Restoration Robotics (HAIR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Soliton investors own include Cronos Group (CRON), Canopy Growth (CGC), NVIDIA (NVDA), Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Micron Technology (MU), Verizon Communications (VZ), Tesla (TSLA), Innovative Industrial Properties (IIPR) and Square (SQ).

Soliton's stock is owned by a variety of of institutional and retail investors. Top institutional investors include University of Texas Texas AM Investment Managment Co. (2.51%), Geode Capital Management LLC (0.51%), State Street Corp (0.49%), Advisor Group Inc. (0.41%), First Republic Investment Management Inc. (0.28%) and Oxford Asset Management LLP (0.11%).

SOLY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Virtu Financial LLC.

SOLY stock was purchased by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., State Street Corp, First Republic Investment Management Inc., Oxford Asset Management LLP, Integrated Advisors Network LLC, Advisor Group Inc., Geode Capital Management LLC and UBS Group AG.

Shares of SOLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SOLY stock can currently be purchased for approximately $11.86.

Soliton has a market capitalization of $200.81 million. Soliton employs 7 workers across the globe.View Additional Information About Soliton.

The official website for Soliton is http://www.soliton.com/.

Soliton's mailing address is 5304 ASHBROOK DRIVE, HOUSTON TX, 77081. The company can be reached via phone at 844-705-4866.